<DOC>
	<DOCNO>NCT01483027</DOCNO>
	<brief_summary>The effectiveness safety TheraSphere evaluate patient colorectal cancer metastasis liver , schedule receive second line chemotherapy . All patient receive standard care chemotherapy without addition TheraSphere .</brief_summary>
	<brief_title>Efficacy Evaluation TheraSphere Following Failed First Line Chemotherapy Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Must male female , 18 year age old , ethnic racial group Not resect primary tumor ; must clinically stable Colorectal cancer unresectable metastatic disease liver ( unresectable unilobar bilobar disease ) disease progression liver oxaliplatin irinotecan base first line chemotherapy Eligible receive secondline standardofcare chemotherapy either 1 ) oxaliplatinbased chemotherapy regimen , 2 ) irinotecanbased chemotherapy regimen Baseline efficacy image measurable target tumor liver accord RECIST 1.1 use standard image technique take within 28 day prior randomization . Images must take , time completion first line chemotherapy Tumor replacement &lt; 50 % total liver volume Eastern Cooperative Oncology Group ( ECOG ) 01 screen first treatment First line chemotherapy regimen complete least 14 day prior initiation 2nd line chemotherapy protocol Patient willing participate study sign study inform consent Serum creatinine ≤ 2.0 mg/dL Serum bilirubin 1.2 x upper limit normal Albumin ≥ 3.0 g/dL Neutrophil count &gt; 1200/cubic mm Exclusion Criteria History hepatic encephalopathy Contraindications angiography selective visceral catheterization bleed diathesis coagulopathy correctable usual therapy hemostatic agent History severe peripheral allergy intolerance contrast agent , narcotic , sedative atropine manage medically Presentation pulmonary insufficiency clinically evident chronic obstructive pulmonary disease Cirrhosis portal hypertension Prior external beam radiation treatment liver Prior intraarterial liver direct therapy , include transcatheter arterial chemoembolization ( TACE ) Y90 microsphere therapy Planned treatment biological agent within 28 day prior receive TheraSphere ( may resume Y90 treatment immediately control arm ) Planned liver direct therapy radiation therapy Intervention , compromise , Ampulla Vater Clinically evident ascites ( trace ascites image acceptable ) Toxicities due prior cancer therapy resolve initiation study treatment , Investigator determine continue complication compromise safe treatment patient Significant lifethreatening extrahepatic disease , include patient dialysis , unresolved diarrhea , serious unresolved infection include patient know human immunodeficiency virus ( HIV ) positive acute hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) confirm extrahepatic metastasis . Limited indeterminate extrahepatic lesion lung and/or lymph node permit ( 5 lesion lung , individual lesion &lt; 1 cm ; number lymph node individual node &lt; 1.5 cm ) Contraindications plan second line standardofcare chemotherapy regimen Women childbearing potential must negative serum pregnancy test within 14 day prior randomization , must breastfeed must agree use contraceptive duration study . Participation clinical trial investigational therapy within 30 day prior randomization Comorbid disease condition would place patient undue risk preclude safe use TheraSphere treatment , Investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>